Children and caregiver proxy quality of life from peanut oral immunotherapy trials.
caregiver proxy
health-related quality of life
oral immunotherapy
peanut allergy
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
26
10
2022
received:
05
07
2022
accepted:
14
11
2022
entrez:
27
12
2022
pubmed:
28
12
2022
medline:
28
12
2022
Statut:
ppublish
Résumé
Health-related quality of life (HRQoL) is significantly and substantially reduced in individuals with peanut allergy due to many factors associated with unanticipated or potentially fatal reactions. Further insight on the impact of peanut oral immunotherapy in managing peanut allergy on HRQoL is needed. The aim of this analysis was to assess effects of peanut (Arachis hypogaea) allergen powder-dnfp (PTAH), a biologic drug for peanut oral immunotherapy, on HRQoL from three phase 3 and two follow-on trials of PTAH. HRQoL assessments from participants aged 4-17 in the PALISADE (ARC003), ARC004 (PALISADE follow-on), ARTEMIS (ARC010), RAMSES (ARC007), and ARC011 (RAMSES follow-on) trials were included in this analysis. Responses on the Food Allergy Quality of Life Questionnaire (FAQLQ) and Food Allergy Independent Measure (FAIM) were evaluated by age group and respondent (self or caregiver proxy). Data were analyzed with descriptive statistics and Student t tests. Baseline FAQLQ and FAIM total scores appeared comparable between PTAH- and placebo-treated participants. Self and caregiver proxy-reported total scores on the FAQLQ for PTAH-treated participants generally improved at trial exit versus baseline; FAIM total scores improved throughout all trials. The tendency for improvement in FAQLQ total scores from baseline for PTAH appeared larger in self versus caregiver proxy-reports. Between treatment groups, PTAH was generally favored in the PALISADE and ARTEMIS trials; differences varied in the RAMSES trial based on age and respondent types. PTAH for the management of peanut allergy in children appeared to have a beneficial effect on HRQoL in trials. Improvements were seen despite rigors of trial participation.
Sections du résumé
BACKGROUND
Health-related quality of life (HRQoL) is significantly and substantially reduced in individuals with peanut allergy due to many factors associated with unanticipated or potentially fatal reactions. Further insight on the impact of peanut oral immunotherapy in managing peanut allergy on HRQoL is needed. The aim of this analysis was to assess effects of peanut (Arachis hypogaea) allergen powder-dnfp (PTAH), a biologic drug for peanut oral immunotherapy, on HRQoL from three phase 3 and two follow-on trials of PTAH.
METHODS
HRQoL assessments from participants aged 4-17 in the PALISADE (ARC003), ARC004 (PALISADE follow-on), ARTEMIS (ARC010), RAMSES (ARC007), and ARC011 (RAMSES follow-on) trials were included in this analysis. Responses on the Food Allergy Quality of Life Questionnaire (FAQLQ) and Food Allergy Independent Measure (FAIM) were evaluated by age group and respondent (self or caregiver proxy). Data were analyzed with descriptive statistics and Student t tests.
RESULTS
Baseline FAQLQ and FAIM total scores appeared comparable between PTAH- and placebo-treated participants. Self and caregiver proxy-reported total scores on the FAQLQ for PTAH-treated participants generally improved at trial exit versus baseline; FAIM total scores improved throughout all trials. The tendency for improvement in FAQLQ total scores from baseline for PTAH appeared larger in self versus caregiver proxy-reports. Between treatment groups, PTAH was generally favored in the PALISADE and ARTEMIS trials; differences varied in the RAMSES trial based on age and respondent types.
CONCLUSIONS
PTAH for the management of peanut allergy in children appeared to have a beneficial effect on HRQoL in trials. Improvements were seen despite rigors of trial participation.
Identifiants
pubmed: 36573312
doi: 10.1002/clt2.12213
pmc: PMC9762119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12213Subventions
Organisme : Aimmune Therapeutics, a Nestlé Health Science company
Informations de copyright
© 2022 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Références
Clin Transl Allergy. 2022 Oct 10;12(10):e12203
pubmed: 36246730
Clin Exp Allergy. 2020 Nov;50(11):1238-1248
pubmed: 32757478
J Allergy Clin Immunol Pract. 2022 Jan;10(1):35-44
pubmed: 34757065
Clin Transl Allergy. 2022 Feb 03;12(2):e12078
pubmed: 35140908
Allergy. 2014 Sep;69(9):1255-7
pubmed: 24925125
J Manag Care Spec Pharm. 2021 Apr;27(4):516-527
pubmed: 33470880
Allergy. 2014 Jul;69(7):845-53
pubmed: 24785644
Allergy. 2017 Dec;72(12):1883-1890
pubmed: 28542911
Clin Exp Allergy. 2011 Oct;41(10):1431-9
pubmed: 21569128
World Allergy Organ J. 2021 Mar 26;14(3):100525
pubmed: 33850602
J Allergy Clin Immunol. 2008 Jul;122(1):139-44, 144.e1-2
pubmed: 18602570
Allergol Int. 2020 Jan;69(1):19-27
pubmed: 31759890
J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1
pubmed: 19767070
Lancet. 2019 Jun 1;393(10187):2222-2232
pubmed: 31030987
Clin Exp Allergy. 2017 Jun;47(6):719-739
pubmed: 28836701
Allergy. 2021 May;76(5):1367-1384
pubmed: 33216994
J Allergy Clin Immunol. 2020 Jan;145(1):127-139
pubmed: 31604088
Allergy. 2014 Jul;69(7):834-44
pubmed: 24836207
Allergy. 2020 Nov;75(11):2899-2908
pubmed: 32400915
Clin Exp Allergy. 2009 Jan;39(1):127-37
pubmed: 19016799
Allergy. 2018 Mar;73(3):560-568
pubmed: 29052245
Allergy. 2020 Oct;75(10):2623-2632
pubmed: 32350869
Allergy. 2022 May;77(5):1347-1359
pubmed: 34647344
J Allergy Clin Immunol Pract. 2019 Feb;7(2):479-491.e10
pubmed: 30423449
Pediatr Allergy Immunol. 2018 Aug;29(5):527-537
pubmed: 29660855
Allergy. 2019 Apr;74(4):831-834
pubmed: 30475393
Allergol Select. 2021 Jul 8;5:195-243
pubmed: 34263109
J Allergy Clin Immunol Pract. 2021 Jan;9(1):216-224.e1
pubmed: 32841748
Allergy. 2011 Dec;66(12):1580-9
pubmed: 21958234
Lancet. 2014 Apr 12;383(9925):1297-1304
pubmed: 24485709
Curr Treat Options Allergy. 2021;8(1):9-20
pubmed: 33520599
J Allergy Clin Immunol Pract. 2021 May;9(5):1879-1889.e13
pubmed: 33359589
Pediatr Allergy Immunol. 2019 Sep;30(6):638-645
pubmed: 31013372
Allergy. 2010 May;65(5):630-5
pubmed: 19845570
Clin Exp Allergy. 2010 Mar;40(3):476-85
pubmed: 20210816
J Allergy Clin Immunol. 2014 Jan;133(1):91-7.e1-6
pubmed: 23932458
N Engl J Med. 2018 Nov 22;379(21):1991-2001
pubmed: 30449234
Chem Immunol Allergy. 2015;101:221-6
pubmed: 26022882
Allergy. 2022 Mar;77(3):991-1003
pubmed: 34320250
World Allergy Organ J. 2021 Feb 15;14(2):100512
pubmed: 33664934
Lancet Child Adolesc Health. 2020 Oct;4(10):728-739
pubmed: 32702315
Ann Allergy Asthma Immunol. 2020 Apr;124(4):379-384
pubmed: 31931105
J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):363-368.e2
pubmed: 28017626
Allergy. 2010 Aug;65(8):933-45
pubmed: 20180792
Allergy Asthma Clin Immunol. 2014 Nov 25;10(1):57
pubmed: 25788951
Ann Allergy Asthma Immunol. 2020 Aug;125(2):196-201.e1
pubmed: 32278075
J Allergy Clin Immunol Pract. 2019 Feb;7(2):429-436.e2
pubmed: 30129441